Peer-Reviewed Publication of Positive Preclinical Data of SiSaf ’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

GUILDFORD, United Kingdom, Sept. 18, 2023. SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic Acids(1) of positive in vivo data demonstrating the safety and efficacy...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials